In this insightful discussion, Amer Zeidan from Yale and Rena Buckstein from Sunnybrook share their expert views on treating lower-risk myelodysplastic syndromes (MDS). They highlight the importance of accurate diagnosis with bone marrow examinations and prognostic tools. Guillermo Garcia-Manero from MD Anderson dives into innovative treatments like erythropoiesis-stimulating agents and Luspatercept, while Andrew Brunner emphasizes the complexities of dosing. They advocate for improved strategies and collaboration to enhance patient care and outcomes.